Beta Drugs H1 FY27 Revenue Rises to ₹263 Cr; PAT Grows 13.1%
Beta Drugs Limited reported H1 FY27 revenue of ₹263 crore, a 12.9% increase year-on-year. PAT grew by 13.1% to ₹34 crore. Gross margins improved to 56.2%, and EBITDA margins stood at 23.2%. The Branded Oncology segment grew 17%, and API business increased by ~30%. The company invested ₹35 crore in API capacity expansion.
The announcement details strong financial performance, strategic growth initiatives across key business segments (Oncology, API, Exports), and substantial investments in capacity expansion, which are material to investors.
The company reported strong revenue and profit growth, improved margins, and significant investments in capacity expansion, indicating positive business performance and future outlook.
Beta Drugs Limited has reported its financial results for the first half of FY27, showcasing significant growth across key business segments amidst challenging global macroeconomic conditions. The company's revenue for H1 FY27 reached ₹263 crore, marking a 12.9% increase compared to H1 FY26. Profit After Tax (PAT) also demonstrated robust growth, increasing by 13.1% to ₹34 crore.
The company highlighted strong performance in its Branded Oncology segment, which grew by 17% to approximately ₹71 crore in H1 FY27. The Oral Solid Dosage (OSD) contribution within this segment grew to about 50%, driven by brand-building initiatives and new product launches. Beta Drugs also reported empanelment with Tata Memorial Hospital for five products.
The API business saw a growth of approximately 30%, with new capacity expansion expected to go onstream in Q4 FY27. The CMO business registered a growth of 21% for H1 FY27, driven by new customer additions and an expanding supply pipeline. Exports contributed ₹43 crore, with 76 dossiers submitted and 35 approvals received in H1 FY27 across focused geographies.
Gross Margins improved to 56.2% from 51.4% year-on-year, and EBITDA margins expanded to 23.2%. The company has invested approximately ₹35 crore towards expansion of API capacity and backward integration, with a total investment of ₹26 crore in API capacity expansion and backward integration up to H1 FY27.
Beta Drugs is on track to achieve its Vision 2030, aiming to become a global specialty pharmaceutical company. The company's strategic focus includes deeper penetration in key accounts, expanding institutional sales, and strengthening its brand positioning. The presentation also detailed the company's integrated manufacturing setup and its robust R&D process.
What to do with a filing like this
Beta Drugs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Beta Drugs Limited. Read the original for the full detail.